Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus SERNIVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus SERNIVO.
CAPEX vs SERNIVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply a thin layer to affected area twice daily for up to 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid